首页|左侧乳腺癌保乳术后IMRT与Hybrid技术的剂量学差异

左侧乳腺癌保乳术后IMRT与Hybrid技术的剂量学差异

扫码查看
目的 比较左侧乳腺癌保乳术后调强适形放疗(IMRT)与Hybrid技术的剂量学差异.方法 30例左侧乳腺癌保乳术后患者在腹式深吸气屏气方式下行CT检查后,分别设计IMRT和Hybrid两种放疗计划,并对计划靶区和危及器官的剂量学参数进行比较.结果 两种放疗计划的计划靶区平均剂量(Dmean)以及心脏Dmean、接受5 Gy照射的体积百分比(V5)和冠状动脉左前降支(LAD)V40比较均无统计学差异(P>0.05);放疗计划使用IMRT技术的均匀性指数、适形度指数及跳数高于Hybrid技术(P<0.05),而左肺Dmean、V5、V20和V30、心脏最大剂量及LAD Dmean低于Hybrid技术(P<0.05).结论 两种放疗计划在左侧乳腺癌保乳术后均能达到靶区剂量和危及器官的限值要求.相对而言,Hybrid技术在靶区剂量分布上具有较好的适形度、均匀性以及较低的跳数,而IMRT技术在左肺的保护上更具有优势.
Dosimetry differences between IMRT and Hybrid techniques after left breast-conserving therapy
Objective To compare the dosimetry differences between intensity-modulated radiation therapy(IMRT)and Hybrid techniques after left breast-conserving surgery.Methods Thirty patients accepted CT examination via abdominal deep inspiration breath holding after left breast-conserving surgery.Then two radiotherapy plans including IMRT and Hybrid techniques were designed for each patient according to CT images,and the dosimetry parameters of the planned target area and organ at risk were compared.Results There were no statistical differences in the mean dose(Dmean)of planned target area,Dmean and volume percentage receiving 5 Gy(V5)of heart and V40 of left anterior descending coronary artery(LAD)between the two radiotherapy plans(P>0.05).The homogeneity index,conformity index and monitor unit of radiotherapy plan using IMRT technique were higher,while the Dmean,V5,V20 and V30 of left lung,maximum dose of heart and Dmean of LAD were lower than those using Hybrid technique(P<0.05).Conclusion Both radiotherapy plans can meet the dose of target area and limit requirement of organ at risk after left breast-conserving surgery.Relatively,Hybrid technique has a better homogeneity and conformity and less monitor unit in the dose distribution of target area,while IMRT technique is superior in the protection of left lung.

Intensity-modulated radiation therapyHybrid techniqueBreast cancerDosimetry difference

滕芸、张炎、胡望远

展开 >

321015 浙江金华,温州医科大学附属金华医院放疗科

调强适形放疗 Hybrid技术 乳腺癌 剂量学差异

浙江省金华市科技局重点项目

2022-3-119

2024

江苏医药
江苏省人民医院(南京医科大学第一附属医院)

江苏医药

影响因子:0.707
ISSN:0253-3685
年,卷(期):2024.50(5)
  • 16